Aurinia Pharmaceuticals Inc.
AUPHDrugs in Pipeline
7
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Jul 30, 2026
6wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
Ciclosporin
Psoriasis
Voclosporin
Lupus Nephritis
0.05% Voclosporin Ophthalmic Solution (VOS)
Dry Eye Syndrome
Aritinercept
Myasthenia Gravis, Generalized
tacrolimus
Kidney Diseases
Voclosporin High Dose
Lupus Nephritis
Voclosporin Ophthalmic Solution
Dry Eye
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ciclosporin | Phase 3 | Psoriasis | - | - |
Voclosporin | Phase 3 | Lupus Nephritis | - | - |
0.05% Voclosporin Ophthalmic Solution (VOS) | Phase 3 | Dry Eye Syndrome | - | - |
Aritinercept | Phase 2 | Myasthenia Gravis, Generalized | - | - |
tacrolimus | Phase 2 | Kidney Diseases | - | - |
Voclosporin High Dose | Phase 2 | Lupus Nephritis | - | - |
Voclosporin Ophthalmic Solution | Phase 2 | Dry Eye | - | - |
Lupus Nephritis
3 drugs in this indication
Psoriasis
2 drugs in this indication
Kidney Diseases
1 drug in this indication
Dry Eye Syndrome
1 drug in this indication
Dry Eye
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)